Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma
Targeted therapies are the mainstay of treatment for metastatic renal cell carcinoma (mRCC) (National Comprehensive Cancer Network, 2017). These agents inhibit common molecular pathways that are dysfunctional in mRCC including the vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways. Food and Drug Administration (FDA)-approved therapies for mRCC that inhibit the VEGF pathway include pazopanib, sunitinib, cabozantinib, lenvatinib, bevacizumab, axitinib, and sorafenib (National Comprehensive Cancer Network, 2017).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: MacKenzie Crist, Elizabeth Hansen, Lipika Chablani, Elizabeth Guancial Tags: Review Source Type: research
More News: Avastin | Bleeding | Cancer | Cancer & Oncology | Carcinoma | Food and Drug Administration (FDA) | Hematology | Kidney Cancer | Renal Cell Carcinoma